1-3 of 3
Darren R. Veach
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia

Nicholas C. Wolff, Darren R. Veach, William P. Tong, William G. Bornmann, Bayard Clarkson, Robert L. Ilaria, Jr
Journal: Blood
Blood (2005) 105 (10): 3995–4003.
https://doi.org/10.1182/blood-2004-09-3534
Published: 2005
Journal Articles

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor

Nikolas von Bubnoff, Darren R. Veach, Heiko van der Kuip, Walter E. Aulitzky, Jana Sänger, Petra Seipel, William G. Bornmann, Christian Peschel, Bayard Clarkson, Justus Duyster
Journal: Blood
Blood (2005) 105 (4): 1652–1659.
https://doi.org/10.1182/blood-2004-06-2445
Published: 2005
Journal Articles

A Cell-Based Screening Method for Resistance of Bcr-Abl Positive Leukemia Identifies the Mutation Pattern for an Alternative Abl Kinase Inhibitor.

Nikolas von Bubnoff, M.D., Darren R. Veach, Ph.D., Heiko van der Kuip, Ph.D., Walter E. Aulitzky, M.D., Jana Saenger, Petra Seipel, William G. Bornmann, Ph.D., Christian Peschel, M.D., Bayard Clarkson, M.D., Justus Duyster, M.D.
Journal: Blood
Blood (2004) 104 (11): 558.
https://doi.org/10.1182/blood.V104.11.558.558
Published: 2004